Denmark’s MinervaX has raised €47.4 million (around $56 million) in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials. When and if the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback